185 related articles for article (PubMed ID: 28636686)
1. Erythema With Nonscarring, Tense Blister Formation Without Circulating Anti-BP180 Antibodies.
Otake-Irie H; Dainichi T; Kabashima K
JAMA Dermatol; 2017 Nov; 153(11):1185-1186. PubMed ID: 28636686
[No Abstract] [Full Text] [Related]
2. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
[No Abstract] [Full Text] [Related]
3. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
4. Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients.
Ma L; Wang M; Wang X; Chen X; Zhu X
J Dermatol Sci; 2015 Apr; 78(1):76-7. PubMed ID: 25797173
[No Abstract] [Full Text] [Related]
5. Sensitivities and utility of non-invasive serological tests in the diagnosis of bullous pemphigoid.
Yew YW; Tey HL
Int J Dermatol; 2016 Sep; 55(9):e510-1. PubMed ID: 27028937
[No Abstract] [Full Text] [Related]
6. Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid.
Kamata M; Asano Y; Shida R; Maeda N; Yoshizaki A; Miyagaki T; Kawashima T; Tada Y; Sato S
J Dermatol; 2019 Jun; 46(6):e216-e217. PubMed ID: 30628103
[No Abstract] [Full Text] [Related]
7. A case of pemphigoid vegetans with autoantibodies against both BP180 and BP230 antigens.
Suda-Takayanagi T; Hara H; Ohyama B; Hashimoto T; Terui T
J Am Acad Dermatol; 2011 Jan; 64(1):206-8. PubMed ID: 21167421
[No Abstract] [Full Text] [Related]
8. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
9. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
Di Zenzo G; Thoma-Uszynski S; Fontao L; Calabresi V; Hofmann SC; Hellmark T; Sebbag N; Pedicelli C; Sera F; Lacour JP; Wieslander J; Bruckner-Tuderman L; Borradori L; Zambruno G; Hertl M
Clin Immunol; 2008 Sep; 128(3):415-26. PubMed ID: 18571472
[TBL] [Abstract][Full Text] [Related]
10. Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.
Kamiya K; Aoyama Y; Noda K; Miyake T; Yamaguchi M; Hamada T; Tokura Y; Iwatsuki K
J Dermatol Sci; 2015 Apr; 78(1):77-9. PubMed ID: 25771164
[No Abstract] [Full Text] [Related]
11. Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE.
Salz M; Haeberle S; Hoffmann J; Enk AH; Hadaschik EN
J Dermatol Sci; 2017 Sep; 87(3):309-311. PubMed ID: 28823642
[No Abstract] [Full Text] [Related]
12. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
[TBL] [Abstract][Full Text] [Related]
13. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects.
Wieland CN; Comfere NI; Gibson LE; Weaver AL; Krause PK; Murray JA
Arch Dermatol; 2010 Jan; 146(1):21-5. PubMed ID: 20083688
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a patient with strongly suspected bullous pemphigoid in a ward by oral health care providers.
Kanda N; Soga Y; Meguro M; Tanabe A; Yagi Y; Himuro Y; Fujiwara Y; Takashiba S; Kobayashi N
Int J Dent Hyg; 2011 May; 9(2):159-62. PubMed ID: 21356008
[TBL] [Abstract][Full Text] [Related]
15. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
[No Abstract] [Full Text] [Related]
16. Pustular psoriasis associated with bullous pemphigoid with fluctuating anti-BP180 antibody titre according to the condition of pustular lesions.
Otani Y; Hayashi S; Kaneko Y; Koike M; Gommori T; Hamasaki Y; Igawa K
Eur J Dermatol; 2021 Feb; 31(1):107-109. PubMed ID: 33648907
[No Abstract] [Full Text] [Related]
17. A case of childhood bullous pemphigoid with IgG and IgA autoantibodies to various domains of BP180.
Osawa M; Ueda-Hayakawa I; Isei T; Yoshimura K; Fukuda S; Hashimoto T; Okamoto H
J Am Acad Dermatol; 2014 Jun; 70(6):e129-31. PubMed ID: 24831331
[No Abstract] [Full Text] [Related]
18. Bullous pemphigoid with linear lesions and antibodies exclusively against the soluble ectodomain of BP180 (LAD-1).
Mahmoudi H; Toosi R; Kamyab K; Zillikens D; Schmidt E; Daneshpazhooh M
J Dtsch Dermatol Ges; 2019 Sep; 17(9):933-935. PubMed ID: 31353797
[No Abstract] [Full Text] [Related]
19. Role of BP180NC16a-enzyme-linked immunosorbent assay (ELISA) in the diagnosis of bullous pemphigoid in China.
Feng S; Lin L; Jin P; Wu Q; Zhou W; Sang H; Shao C
Int J Dermatol; 2008 Jan; 47(1):24-8. PubMed ID: 18173596
[TBL] [Abstract][Full Text] [Related]
20. [Anti-desmoglein 1 and 3 antibody, anti-BP180(NC16a) antibody, anti-BP230 antibody].
Amagai M
Nihon Rinsho; 2010 Jun; 68 Suppl 6():614-7. PubMed ID: 20942145
[No Abstract] [Full Text] [Related]
[Next] [New Search]
